NDT Advance Access originally published online on February 1, 2007
Nephrology Dialysis Transplantation 2007 22(4):1100-1106; doi:10.1093/ndt/gfl759
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association between the metabolic syndrome and chronic kidney disease in Chinese adults
1Department of Medicine, Tulane University School of Medicine, 2Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, 3the Cardiovascular Institute and Fuwai Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College and 4Chinese National Center for Cardiovascular Disease Control and Research, Beijing, China
Correspondence and offprint requests to: Jing Chen, MD, MSc, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL-45, New Orleans, LA 70112. Email: jchen{at}tulane.edu
| Abstract |
|---|
|
|
|---|
Background. The metabolic syndrome is a common risk factor for cardiovascular and chronic kidney disease (CKD) in Western populations. We examined the relationship between the metabolic syndrome and risk of CKD in Chinese adults.
Methods. A cross-sectional survey was conducted in a nationally representative sample of 15 160 Chinese adults aged 3574 years. The metabolic syndrome was defined as the presence of three or more of the following risk factors: elevated blood pressure, low high density lipoprotein (HDL)-cholesterol, high triglycerides, elevated plasma glucose and abdominal obesity. CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m2 and elevated serum creatinine was defined as
1.14 mg/dl in men and
0.97 mg/dl in women (
95th percentile of serum creatinine in Chinese men and women aged 3544 years without hypertension or diabetes, respectively).
Results. The multivariate-adjusted odds ratios [95% confidence interval (CI)] of CKD and elevated serum creatinine in participants with compared to those without the metabolic syndrome were 1.64 (1.16, 2.32) and 1.36 (1.07, 1.73), respectively. Compared to participants without any components of the metabolic syndrome, the multivariate-adjusted odds ratios (95% CI) of CKD were 1.51 (1.02, 2.23), 1.50 (0.97, 2.32), 2.13 (1.30, 3.50) and 2.72 (1.50, 4.93) for those with 1, 2, 3, and 4 or 5 components, respectively. The corresponding multivariate-adjusted odds ratios (95% CI) of elevated serum creatinine were 1.11 (0.88, 1.40), 1.39 (1.07, 2.04), 1.47 (1.06, 2.04) and 2.00 (1.32, 3.03), respectively.
Conclusions. These findings suggest that the metabolic syndrome might be an important risk factor for CKD in Chinese adults.
Keywords: China; chronic kidney disease; cross-sectional studies; diabetes; metabolic syndrome; obesity
| Introduction |
|---|
|
|
|---|
Chronic kidney disease (CKD) has become a global public health challenge because of its high prevalence [13] and the concomitant increase in risk of end-stage renal disease (ESRD), cardiovascular disease (CVD) and premature death [46]. Patients with ESRD have a poorer quality of life and a shorter life expectancy compared with individuals of the same age in the general population [4]. A better understanding of the aetiology of CKD, leading to early detection and prevention and effective therapy might alleviate the future burden of ESRD, CVD, and its associated mortality.
The metabolic syndrome, characterized by a clustering of abdominal obesity, hypertriglyceridaemia, low high-density lipoprotein (HDL) cholesterol, elevated blood pressure (BP), and high fasting glucose, has been associated with an increased risk for the development of diabetes and CVD as well as an increased mortality from CVD and all-causes [7,8]. A few epidemiological studies in the US adult population have reported that the metabolic syndrome is associated with CKD and microalbuminuria [9,10]. However, the relationship between the metabolic syndrome and risk of CKD has not been studied in the Chinese population, a group that still has a low prevalence of CKD and obesity [3,11]. The objective of the present study was to examine the association between the metabolic syndrome and risk of CKD in a large representative sample of Chinese adults who participated in the International Collaborative Study of Cardiovascular Disease in ASIA (InterASIA) study.
| Subjects and methods |
|---|
|
|
|---|
Study population
InterASIA was a cross-sectional study of CVD risk factors conducted during 20002001 in China and Thailand. The InterASIA study used a four-stage stratified sampling method to select a nationally representative sample of the general population aged 3574 years in China. The sampling process was stratified by rural vs urban areas and north vs south. A total of 19 012 persons were randomly selected from 20 primary sampling units (street districts in urban or townships in rural) and invited to participate. A total of 15 838 persons (7684 men and 8154 women) completed the survey and examination. The overall response rate was 83.3% (82.1% in men and 84.5% in women; and 82.2% in urban and 84.4% in rural areas). The analysis reported in this article was restricted to adults aged 3574 years who had complete laboratory results (n = 15 160).
The Institutional Review Board at the Tulane University Health Sciences Center and ethics committees and other relevant regulatory bodies in China approved the InterASIA study. Informed consent was obtained from each participant prior to data collection.
Data collection
Information on demographic characteristics, including age, sex, education, occupation and household income was collected during the clinic visits by trained research staff using a standard questionnaire. The interview included questions related to the diagnosis and treatment of hypercholesterolaemia, hypertension and diabetes.
During the clinical examination, BP and anthropometric measurements were collected by trained and certified observers using standard protocols and technique [12]. Three BP measurements were obtained with the participant in a seated position after 5 min of rest. Participants were advised to avoid cigarette smoking, alcohol, caffeinated beverages, and exercise for at least 30 min prior to their BP measurement. Body weight and height were measured twice during the examination. Weight and height were measured in light indoor clothing without shoes. Waist circumference was measured at 1 cm above the navel at minimal respiration.
Overnight fasting blood specimens were collected for measurement of serum lipids, plasma glucose and serum creatinine. Blood specimens were only collected from those who had fasted overnight for a minimum of 10 h. Blood specimens were processed at the examination centre and shipped to a central clinical laboratory in Beijing where they were stored at 70°C until laboratory assays could be performed. Plasma glucose was measured using a modified hexokinase enzymatic method. Serum cholesterol and triglyceride levels were analysed enzymatically using commercially available reagents. The study laboratory was standardized for lipid measurements according to the criteria of the US CDC-NHLBI Lipid Standardization Programs [13].
Serum creatinine was measured by the modified kinetic Jaffe reaction on a Hitachi 7060 Clinical Analyser (Hitachi High-Technologies Corporation, Japan) using commercial reagents. A random sample of 60 serum specimens was sent to the Cleveland Clinic Laboratory (Cleveland, OH) for measurement of serum creatinine. This was the laboratory where serum creatinine levels for the Modification of Diet in Renal Disease (MDRD) Study were measured [14]. On average, serum creatinine assays on the same samples were 2.99 µmol/l (0.0338 mg/dl) higher in the Cleveland Clinic Laboratory than in the InterASIA Study laboratory. Therefore, serum creatinine measurements among study participants were calibrated by adding this difference.
Study outcome and risk factors
Glomerular filtration rate (GFR) was estimated from the simplified equation developed using MDRD data [14]: Estimated GFR = 186.3 x (serum creatinine in mg/dl) 1.154 x age 0.203 x (0.742 for women) x (1.212 if African American). CKD was defined as a GFR < 60 ml/min/1.73 m2 according to the US National Kidney Foundation guidelines [4]. In addition, elevated serum creatinine was used as an outcome measurement because estimated GFR using the MDRD formula has not been validated in the Chinese population. Elevated serum creatinine was defined as
100.8 µmol/l (1.14 mg/dl) in men and
85.7 µmol/l (0.97 mg/dl) in women (
95th percentile of serum creatinine in Chinese men and women aged 3544 years without hypertension or diabetes, respectively).
The metabolic syndrome was defined according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) criteria as the presence of three or more of the following risk factors: waist circumference >102 cm in men or >88 cm in women; serum triglyceride level
1.70 mmol/l (150 mg/dl); HDL-cholesterol level <1.04 mmol/l (40 mg/dl) in men or <1.30 mmol/l (50 mg/dl) in women; BP
130/85 mmHg and/or use of antihypertensive medications; or serum glucose level
6.11 mmol/l (110 mg/dl) and/or use of insulin or hypoglycaemic medication [15]. In a sensitivity analysis, the recent International Diabetes Federation (IDF) definition of metabolic syndrome was used: the presentation of central obesity (defined as waist circumference
90 cm in men and
80 cm in women for Asian populations) plus any two of the following risk factors: triglyceride concentration
1.70 mmol/l (150 mg/dl), or specific treatment for this lipid abnormality; HDL-cholesterol concentration <1.04 mmol/l (40 mg/dl) in men or <1.30 mmol/l (50 mg/dl) in women, or specific treatment for this lipid abnormality; BP
130/85 mmHg, or treatment of previously diagnosed hypertension; or fasting plasma glucose
5.55 mmol/l (100 mg/dl), or previously diagnosed type 2 diabetes [16].
Statistical methods
Age- and sex-adjusted mean values of continuous variables and percentages of categorical variables for exposures, covariates and outcomes were calculated by the metabolic syndrome status. The statistical significance of differences in these characteristics across the metabolic syndrome status was examined by means of the Z test (continuous variables) and the Wald
2 test (categorical variables) in multivariate regression models after adjustment for age and sex. The prevalence of CKD or elevated serum creatinine was determined for participants with and without each of the five components of the metabolic syndrome. The prevalence of CKD or elevated serum creatinine was also calculated by the number of the metabolic syndrome components present.
The age and sex-adjusted, and multivariate-adjusted [adjustment for age, sex, non-steroidal anti-inflammatory drug (NSAID) use in the past month, a high school education, physical inactivity, alcohol drinking, current and former smoking and body mass index (BMI)] odds ratio of CKD or elevated serum creatinine associated with each component of the metabolic syndrome was calculated using logistic regression models. The adjusted odds ratios of CKD or elevated serum creatinine were also determined by clustering of the components of the metabolic syndrome. In these analyses, the odds ratios of CKD or elevated serum creatinine were calculated comparing participants with 1, 2, 3 and 4 or 5 components of the metabolic syndrome to persons without any component of the metabolic syndrome. Because only a few participants had all 5 components of the metabolic syndrome, participants with 4 or 5 components were considered together as a single group. Finally, the adjusted odds ratios of CKD and elevated serum creatinine were calculated for participants with the metabolic syndrome (
3 components) compared with their counterparts without the metabolic syndrome (<3 components).
Hypertension and diabetes are the most important established risk factors for CKD. We examined the association of CKD and elevated serum creatinine with the metabolic syndrome after excluding patients with hypertension and diabetes, separately. Hypertension was defined as systolic BP
140 mmHg and/or diastolic BP
90 mmHg and/or current use of antihypertensive medication. Diabetes was defined as a self-reported history of a prior diagnosis of diabetes or fasting plasma glucose
7.0 mmol/l (126 mg/dl). In addition, we examined the association of CKD and elevated serum creatinine with the metabolic syndrome defined by the IDF criteria. All data analyses were conducted using SUDAAN (Version 8.0; Research Triangle Institute, Research Triangle Park, NC).
| Results |
|---|
|
|
|---|
The general characteristics of study participants are presented by metabolic syndrome status in Table 1. Mean serum creatinine was similar, but estimated-GFR was lower among persons with the metabolic syndrome compared with those without. The percent of persons with CKD and elevated serum creatinine was statistically significantly higher among those with compared to their counterparts without the metabolic syndrome.
|
Table 2 compares the age and sex-adjusted proportion of participants with CKD and elevated serum creatinine, separately, among those with and without each component of the metabolic syndrome. Low HDL-cholesterol, elevated plasma glucose and abdominal obesity were statistically significantly associated with an increased prevalence of CKD or elevated serum creatinine. Furthermore, there was a significant dose-response relationship between the number of metabolic syndrome components and the prevalence of CKD or elevated serum creatinine (P < 0.0001 and P = 0.002, respectively, Figure 1).
|
|
Age, sex-adjusted and multivariate-adjusted odds ratios of CKD associated with individual and multiple components of the metabolic syndrome are presented in Table 3. In the multivariate models, elevated fasting plasma glucose and abdominal obesity were statistically significantly associated with an increased odds ratio of CKD, while low HDL-cholesterol was borderline significantly associated with an increased odds ratio of CKD. Participants with 1, 2, 3 and 4 or 5 components of the metabolic syndrome had a 1.51, 1.50, 2.13 and 2.72-fold increased odds of CKD, respectively, compared with those without any component. Overall, persons with the metabolic syndrome had a 64% increase in the odds of CKD compared with their counterparts without the metabolic syndrome. Similarly, a low HDL-cholesterol, elevated fasting plasma glucose and abdominal obesity were statistically significantly associated with an increased risk of elevated serum creatinine (Table 4). There was a positive and graded association between the numbers of metabolic syndrome components and the odds of elevated serum creatinine. Compared with those without the metabolic syndrome, persons with the metabolic syndrome had a 36% increase in the odds of elevated serum creatinine. The associations between metabolic syndrome and CKD or elevated serum creatinine were consistent in men and women (data not shown).
|
|
Sensitivity analysis
After excluding study participants with hypertension, the metabolic syndrome was significantly associated with an increased odds of CKD (odds ratio 1.74; 95% CI 1.003.02; P = 0.05) and borderline significantly associated with an increased odds of elevated serum creatinine (odds ratio 1.38; 95% CI 0.942.02; P = 0.1) in the multivariate-adjusted models. After excluding patients with treated diabetes, the metabolic syndrome was significantly associated with increased odds of CKD (odds ratio 1.46; 95% CI 1.022.07; P = 0.04) or increased odds of elevated serum creatinine (odds ratio 1.29; 95% CI 1.011.64; P = 0.04) in the multivariate-adjusted models.
The metabolic syndrome according to the IDF definition was similarly associated with an increased risk of CKD and elevated serum creatinine. For example, the odds ratio (95% CI) associated with the metabolic syndrome was 1.50 (1.032.18; P = 0.03) for CKD and 1.42 (1.111.82; P = 0.01) for elevated serum creatinine, respectively, after adjustment for age, sex, NSAID use, high school education, physical inactivity, alcohol drinking, cigarette smoking and BMI.
| Discussion |
|---|
|
|
|---|
The present study identified a strong, positive, and significant relationship between the metabolic syndrome and risk of CKD in the general adult population of China. The risk of CKD increased progressively with a higher number of components of the metabolic syndrome. These relationships were independent of age, sex, and other potential risk factors for CKD, including NSAID use, education, physical activity, alcohol drinking, cigarette smoking and BMI. Our findings are noteworthy because they are based on a large, representative sample of the Chinese general adult population. In addition, careful measures of study exposure and outcome variables allowed for precise estimation of the association.
To our knowledge, this study is the first to report a strong relationship between the metabolic syndrome and the risk of CKD among Chinese adults. These findings have important clinical and public health implications because the metabolic syndrome and CKD are becoming common in the Chinese general population [3,11]. The current study provides new and important information regarding the relationship between the metabolic syndrome and risk of CKD in a representative sample of the Chinese general adult population and suggests that prevention and treatment of the metabolic syndrome should be an important priority for reducing the prevalence of CKD and its associated disease burden in China.
Several studies have examined the association between insulin resistance, metabolic syndrome, and risk of CKD [9,10,17]. We reported that the metabolic syndrome was associated with a 2.60- and 1.89-fold increased risk of CKD and microalbuminuria, respectively, in US adults [9]. Tanaka and colleagues found that metabolic syndrome was significantly associated with CKD (odds ratio 1.54, 95% CI 1.281.85, P < 0.0001) among 6980 participants aged 3079 years in a hospital-based screening program in Okinawa, Japan [17]. In the current study, the odds ratio of CKD associated with the metabolic syndrome was not as high as in the US, but similar to Japanese adult populations. In the US, diabetes and hypertension are the most common underlying causes of CKD [2,4]. However, it has been reported that glomerulonephritis is the most common cause of CKD in the Chinese population [18]. This might also explain the lack of a significant association between elevated BP and CKD in the present study.
A few epidemiology studies examined the association between obesity and risk of CKD and reported inconsistent findings [1922]. In a cohort study of 101 516 Japanese men and women, BMI was inversely related to risk of ESRD in women but not in men [19]. In a cross-sectional analysis of the MDRD experience, percentage of body fat and BMI was positively associated with GFR in patients with renal disease [20]. In an analysis of data from 9082 US adults aged 3074 years, who participated in the second National Health and Nutrition Examination Survey (NHANES II), Stengel and colleagues [21] reported that severe obesity (BMI
35) was associated with a significantly elevated risk of ESRD, but overweight (BMI 25.029.9) and obesity (BMI 3034.9) were not. Vupputuri and Sandler [22] reported a positive and significant association between BMI and nephrosclerosis in women only. BMI was not associated with other types of CKD in that case-control study. In the present study, waist circumference was associated with an increased risk of CKD, which was consistent with our previous findings from NHANES III [9]. These data suggest that abdominal obesity might be an important modifiable risk factor for CKD.
Our study has several limitations. First, the cross-sectional study design in the InterASIA study makes it difficult to draw inferences regarding causality between the metabolic syndrome and risk of CKD. Second, GFR was not directly measured and estimated-GFRs using a serum creatinine-based equation were used to define CKD in our study. The MDRD-equation might have overestimated or underestimated the actual GFR in the Chinese population because it was developed primarily in Caucasian populations in the US [23]. However, we identified a similar relationship between the metabolic syndrome and elevated serum creatinine. Serum creatinine levels and GFR estimated by the MDRD equation have been used widely in clinical practice for the assessment of CKD. Therefore, the findings from our study are applicable to clinical and public health practice settings. In addition, we did not measure urinary protein excretion in this study population which certainly underestimated the prevalence of CKD. Furthermore, a single serum creatinine value was used to estimate kidney function which might lead to the misclassification of CKD. This random measurement error, due to day-to-day variation in serum creatinine levels in individuals, is likely to bias the association toward zero. Finally, the ATP III definition of metabolic syndrome might not be suitable for a Chinese population. Using the IDF definition, however, we also documented a positive and significant association between the metabolic syndrome and risk of CKD in the present study.
In conclusion, our study indicates that the metabolic syndrome is a strong and independent risk factor for CKD in the Chinese general adult population. In addition, there is a graded relationship between the number of the metabolic syndrome components and risk of CKD. These findings warrant future prospective and interventional studies to test the impact of preventing and treating the metabolic syndrome on the risk of CKD.
| Acknowledgement |
|---|
|
|
|---|
The study was funded by a contractual agreement between Tulane University, LA and Pfizer Inc., NY, and partially supported by a grant (U01 DK60963) from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Dr. Chen received partial support for the analysis and interpretation of these data from the Tulane Interdisciplinary Women's Health Research Scholarships Program, funded by the National Institutes of Health (K12-HD043451), Bethesda, MD.
Conflict of Interest Statement. None declared.
| Refernces |
|---|
|
|
|---|
- Meguid El, Nahas A, Bello AK. (2005) Chronic kidney disease: the global challenge. Lancet 365:331340.[Web of Science][Medline]
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:112.[Web of Science][Medline]
- Chen J, Wildman RP, Gu D, et al. (2005) Prevalence of chronic kidney disease in Chinese adult population. Int Kidney 68:28372845.
- Kidney Disease Outcome Quality Initiative, Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis (2002) 39:S1S246.[CrossRef][Web of Science][Medline]
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:12961305.
[Abstract/Free Full Text] - Muntner P, He J, Hamm L, Loria C, Whelton PK. (2002) Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745753.
[Abstract/Free Full Text] - Reynolds K and He J. (2005) Epidemiology of metabolic syndrome. Am J Med Sci 330:273279.[CrossRef][Web of Science][Medline]
- Ford ES. (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:17691778.
[Abstract/Free Full Text] - Chen J, Muntner P, Hamm LL, et al. (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167174.
[Abstract/Free Full Text] - Kurella M, Lo JC, Chertow GM. (2005) Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:21342140.
[Abstract/Free Full Text] - Gu D, Reynolds K, Wu X, et al. (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365:13981405.[CrossRef][Web of Science][Medline]
- Perloff D, Grim C, Flack J, et al. (1993) Human blood pressure determination by sphygmomanometry. Circulation 88:24602470.
- Myers GL, Cooper GR, Winn CL, Smith SJ. (1989) The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 9:105135.[Web of Science][Medline]
- Levey AS, Greene T, Kusek JW, Beck GJ. MDRD Study Group. (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155A (abstract A0828).
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285:24862497.
[Free Full Text] - The IDF consensus worldwide definition of the metabolic syndrome. (http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf). Accessed August 12, 2005.
- Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. (2006) Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 69:369374.[CrossRef][Web of Science][Medline]
- Dialysis and Transplantation Registration Group. (2001) The report about the registration of dialysis and transplantation in China 1999. Chin J Nephrol 17:7778.
- Iseki K, Ikemiya Y, Fukiyama K. (1997) Predictors of end-stage renal disease and body mass index in a screened cohort. Kidney Int 63:S169S170.
- Kopple JD, Greene T, Chumlea WC, et al. (2000) Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57:16881703.[CrossRef][Web of Science][Medline]
- Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. (2003) Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 14:479487.[Web of Science][Medline]
- Vupputuri S and Sandler DP. (2003) Lifestyle risk factors and chronic kidney disease. Ann Epidemiol 13:712720.[CrossRef][Web of Science][Medline]
- Zuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY. (2005) Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 45:463472.[CrossRef][Web of Science][Medline]
Accepted in revised form: 22.11.06
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Yu, D.-R. Ryu, S.-J. Kim, K.-B. Choi, and D.-H. Kang Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey Nephrol. Dial. Transplant., September 24, 2009; (2009) gfp483v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K.-T. Li, B. C.-H. Kwan, C. C. Szeto, and G. T.-C. Ko Metabolic syndrome in peritoneal dialysis patients NDT Plus, August 1, 2008; 1(4): 206 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Nerpin, U. Riserus, E. Ingelsson, J. Sundstrom, M. Jobs, A. Larsson, S. Basu, and J. Arnlov Insulin Sensitivity Measured With Euglycemic Clamp Is Independently Associated With Glomerular Filtration Rate in a Community-Based Cohort Diabetes Care, August 1, 2008; 31(8): 1550 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ritz Metabolic Syndrome: An Emerging Threat to Renal Function Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 869 - 871. [Full Text] [PDF] |
||||
![]() |
Ar. Mani, J. Radhakrishnan, H. Wang, Al. Mani, M.A. Mani, C. Nelson-Williams, K.S. Carew, S. Mane, H. Najmabadi, D. Wu, et al. Metabolic Syndrome--What We Know and What We Don't Know: LPR6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. Science 315: 1278-1282, 2007 J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1619 - 1623. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






